Date
Time
Star Therapeutics is investigating a once-monthly subcutaneous prophylactic treatment for VWD called VGA039. If you or someone in your family has any type of VWD, please join us for an engaging session as Dr. Benjamin Kim, senior vice president of clinical development at Star Therapeutics, shares how VGA039 works, its clinical development path, and early trial results. Dr. Kim will also discuss Star’s VIVID clinical trials and how to explore eligibility and participate.
About the Speaker
Benjamin Kim, MD, MPhil
Senior Vice President, Clinical Development at Star Therapeutics
Dr. Kim is a hematologist and leads the clinical development of VGA039 at Star Therapeutics. Previously, he oversaw the first Phase 3 trial for Hemlibra at Genentech, led the clinical development team for the ROCTAVIAN hemophilia A gene therapy trials at BioMarin, and oversaw clinical development & operations for MarzAA at Catalyst Biosciences. Prior to joining industry, Dr. Kim was an assistant professor at the University of California, San Francisco, where he cared for adolescent and adult persons with bleeding disorders in the hemophilia treatment center.